Dr Alex Tonks
Prosiectau fel Prif Ymchwiliwr
- CD200: A putative target of AML (01.12.2008 - 30.11.2011)
- Development on an in vivo pre-clinical model to test the blockade of CD200-CD200R using a fully humanised anti-CD200 antibody for the treatment of patients with acute myeloid leukaemia (01.10.2016 - 28.02.2018)
- Exploring NOX2 as a component of multi-target therapy for acute myeloid leukaemia (14.09.2022 - 13.09.2025)
- Identification of therapeutic targets in acute myeloid leukaemia expressing the mutant RAS oncogene (31.03.2010 - 31.03.2014)
- Mechanisms underlying the required expression of S100A4 for proliferation and survival of AML blasts (01.10.2021 - 30.09.2024)
Prosiectau fel Cyd-Ymchwiliwr
- Biomarker discovery for acute myeloid leukaemia using a proteomic approach (01.10.2016 - 31.03.2017)
- Cardiff Experimental Cancer Medicine Centre (01.04.2012 - 31.03.2017)
- Characterisation of the immune stimulatory component of honey (01.04.2008 - 31.03.2009)
- Development of a nanomedicine approach to achieve simultaneous targeting of cancer and bacterial infections (19.11.2018 - 31.12.2020)
- Development of novel CD200:CD200R blockade cancer immunotherapy (01.06.2015 - 31.05.2016)